Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachary Shriver

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Blood|May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Nature Biotechnology|November 9, 2010
Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteinsCarlos J Bosques, Brian E Collins, James W Meador, et al.
Nature Biotechnology|June 10, 2016
The US regulatory and pharmacopeia response to the global heparin contamination crisisAnita Y Szajek, Edward Chess, Kristian Johansen, et al.
Antiviral Research|February 1, 2015
Heparin octasaccharide decoy liposomes inhibit replication of multiple virusesGabriel L Hendricks, Lourdes Velazquez, Serena Pham, et al.
Nature Biotechnology|April 26, 2008
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical eventsMarco Guerrini, Daniela Beccati, Zachary Shriver, et al.
Plos One|June 24, 2011
M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasisHe Zhou, Sucharita Roy, Edward Cochran, et al.
Blood Cancer Journal|November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivoTengteng Yu, Bharat Chaganty, Liang Lin, et al.
Cell|July 21, 2015
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeLuke N Robinson, Kannan Tharakaraman, Kirk J Rowley, et al.
The New England Journal of Medicine|April 25, 2008
Contaminated heparin associated with adverse clinical events and activation of the contact systemTakashi Kei Kishimoto, Karthik Viswanathan, Tanmoy Ganguly, et al.
The New England Journal of Medicine|December 5, 2008
Outbreak of adverse reactions associated with contaminated heparinDavid B Blossom, Alexander J Kallen, Priti R Patel, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Blood|May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Nature Biotechnology|November 9, 2010
Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteinsCarlos J Bosques, Brian E Collins, James W Meador, et al.
Nature Biotechnology|June 10, 2016
The US regulatory and pharmacopeia response to the global heparin contamination crisisAnita Y Szajek, Edward Chess, Kristian Johansen, et al.
Antiviral Research|February 1, 2015
Heparin octasaccharide decoy liposomes inhibit replication of multiple virusesGabriel L Hendricks, Lourdes Velazquez, Serena Pham, et al.
Nature Biotechnology|April 26, 2008
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical eventsMarco Guerrini, Daniela Beccati, Zachary Shriver, et al.
Plos One|June 24, 2011
M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasisHe Zhou, Sucharita Roy, Edward Cochran, et al.
Blood Cancer Journal|November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivoTengteng Yu, Bharat Chaganty, Liang Lin, et al.
Cell|July 21, 2015
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeLuke N Robinson, Kannan Tharakaraman, Kirk J Rowley, et al.
The New England Journal of Medicine|April 25, 2008
Contaminated heparin associated with adverse clinical events and activation of the contact systemTakashi Kei Kishimoto, Karthik Viswanathan, Tanmoy Ganguly, et al.
The New England Journal of Medicine|December 5, 2008
Outbreak of adverse reactions associated with contaminated heparinDavid B Blossom, Alexander J Kallen, Priti R Patel, et al.
Pageof 7